IPO Calendar
Lead Manager
- J P Morgan Chase (490)
- Goldman Sachs (463)
- Morgan Stanley (421)
- Bank of America Merrill Lynch (358)
- Citigroup (222)
- Jefferies (214)
- Credit Suisse (180)
- Barclays (151)
- Cowen and Company (147)
- Deutsche Bank (84)
- Piper Jaffray (70)
- Leerink Partners (70)
- Stifel (65)
- UBS Investment Bank (53)
- Evercore (52)
- RBC Capital (51)
- BMO Capital (49)
- Wells Fargo (47)
- Raymond James (38)
- William Blair (37)
More +
IPO - Pricing (29)
Jefferies
| UnderWriters* | |||||||||||
| Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 16 | BioAtla Inc. | Health-Care | 18 | 10 | JPM | JEFF | CS | 38.7% | 72.3% | ||
| Dec 11 | Certara Inc. | Technology | 23 | 29 | JEFF | MS | BAML | 69.3% | 65.6% | ||
| Dec 4 | Sigilon Therape | Health-Care | 18 | 7 | MS | JEFF | BRCL | 39.8% | 93.2% | ||
| Nov 20 | Maravai LifeSci | Health-Care | 27 | 60 | MS | JEFF | GS | 33.7% | 10.6% | ||
| Nov 19 | Olema Pharmaceu | Health-Care | 19 | 11 | JPM | JEFF | COWN | 13.9% | 157.9% | ||
| Oct 22 | BCLS Acquisitio | Finance | 10 | 12 | GS | JEFF | 8% | 9.9% | |||
| Oct 16 | TARSUS PHARMACE | Health-Care | 16 | 5 | BAML | JEFF | RAYJ | 22.8% | 28.6% | ||
| Oct 16 | Aligos Therapeu | Health-Care | 15 | 10 | JPM | JEFF | PPRJ | 27.6% | -1% | ||
| Oct 9 | Kronos Bio Inc. | Health-Care | 19 | 13 | GS | JEFF | COWN | 28.4% | 42.5% | ||
| Oct 2 | Oncorus Inc. | Health-Care | 15 | 5 | JEFF | EVCR | PPRJ | 12.6% | 6.7% | ||
| Oct 2 | C4 Therapeutics | Health-Care | 19 | 9 | JEFF | EVCR | BMO | 20.3% | 34.2% | ||
| Sep 24 | Taysha Gene The | Health-Care | 20 | 7 | GS | MS | JEFF | 32.9% | 20.3% | ||
| Sep 18 | Athira Pharma I | Health-Care | 17 | 12 | GS | JEFF | Stifel | 26.8% | 0.6% | ||
| Aug 19 | Inhibrx Inc. | Health-Care | 17 | 7 | JEFF | EVCR | CS | 6.4% | 21.5% | ||
| Aug 19 | Harmony Bioscie | Health-Care | 37 | 24 | GS | JEFF | PPRJ | 2.4% | -2.5% | ||
| Aug 14 | CureVac B.V. | Health-Care | 16 | 13 | BAML | JEFF | CS | 178% | 249.4% | ||
| Jul 17 | ALX Oncology Ho | Health-Care | 19 | 8 | JEFF | CS | CNTR | 18.8% | 57.9% | ||
| Jun 26 | Fusion Pharmace | Health-Care | 17 | 12 | MS | JEFF | COWN | 41.3% | 0% | ||
| Jun 19 | Forma Therapeut | Health-Care | 20 | 13 | JEFF | LRNK | CS | 11.3% | 95% | ||
| Jun 5 | Applied Molecul | Health-Care | 14 | 11 | BAML | JEFF | LRNK | 31.6% | 28.4% | ||
| May 8 | Ayala Pharmaceu | Health-Care | 15 | 3 | CITI | JEFF | 47.1% | 0.2% | |||
| May 1 | Lyra Therapeuti | Health-Care | 16 | 3 | BAML | JEFF | WB | 49.7% | 16% | ||
| Apr 24 | ORIC Pharmaceut | Health-Care | 16 | 7 | JPM | CITI | JEFF | 49.3% | 61.1% | ||
| Apr 8 | Keros Therapeut | Health-Care | 16 | 6 | JEFF | LRNK | 17.7% | 25.5% | |||
| Apr 3 | Zentalis Pharma | Health-Care | 18 | 9 | MS | JEFF | GGNH | 20.8% | 28.9% | ||
| Feb 6 | Schrodinger Inc | Health-Care | 17 | 11 | MS | BAML | JEFF | 64.2% | 68.5% | ||
| Feb 6 | Beam Therapeuti | Health-Care | 17 | 10 | JPM | JEFF | BRCL | 55.4% | 10.3% | ||
| Jan 30 | Black Diamond T | Health-Care | 19 | 10 | JPM | JEFF | COWN | 50.6% | 107.8% | ||
| Jan 17 | I-MAB | Health-Care | 14 | 7 | JEFF | CITI | 51.8% | -10.7% | |||
*
Lead manager or one of top three managers in an underwriting team.